The short version of 研究代号 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-23. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
A common assertion in the US and the UK is that heavy consumption of turkey meat—as seen during Thanksgiving and Christmas—results in drowsiness, due to high levels of tryptophan contained in turkey. However, the amount of tryptophan in turkey is comparable with that of other meats. Drowsiness after eating may be caused by other foods eaten with the turkey, particularly carbohydrates. Ingestion of a meal rich in carbohydrates triggers the release of insulin. Insulin in turn stimulates the uptake of large neutral branched-chain amino acids (BCAA), but not tryptophan, into muscle, increasing the ratio of tryptophan to BCAA in the blood stream. The resulting increased tryptophan ratio reduces competition at the large neutral amino acid transporter (which transports both BCAA and aromatic amino acids), resulting in more uptake of tryptophan across the blood–brain barrier into the cerebrospinal fluid (CSF). Once in the CSF, tryptophan is converted into serotonin in the raphe nuclei by the normal enzymatic pathway. The resultant serotonin is further metabolised into the hormone melatonin—which is an important mediator of the circadian rhythm—by the pineal gland. Hence, these data suggest that "feast-induced drowsiness"—or postprandial somnolence—may be the result of a heavy meal rich in carbohydrates, which indirectly increases the production of melatonin in the brain, and thereby promotes sleep.
Buoyancy force = weight of object in empty space − weight of object immersed in fluid The final result would be measured in Newtons. Air's density is very small compared to most solids and liquids. For this reason, the weight of an object in air is approximately the same as its true weight in a vacuum. The buoyancy of air is neglected for most objects during a measurement in air because the error is usually insignificant (typically less than 0.1% except for objects of very low average density such as a balloon or light foam).
where the denominator includes only covalently bound H2CO3 and does not include hydrated CO2(aq). The much smaller and often-quoted value near 4.16 × 10−7 (or pKa1 = 6.38) is an apparent value calculated on the (incorrect) assumption that all dissolved CO2 is present as carbonic acid, so that
Didesmethylcitalopram is an active metabolite of the antidepressant drug citalopram (racemic). Didesmethylescitalopram is an active metabolite of the antidepressant escitalopram, the S-enantiomer of citalopram. Like citalopram and escitalopram, didesmethyl(es)citalopram functions as a selective serotonin reuptake inhibitor (SSRI), and is responsible for some of its parents' therapeutic benefits.
Because common law judges historically gave inadequate remedies for workers who were dismissed, and let employers dictate the terms of dismissal by contract, the Fair Work Act 2009 section 382 contains the right to be "protected from unfair dismissal", if the person is an employee, and under section 383 they have been working for at least 6 months, or one year for an employee of an employer with under 15 staff. Small businesses may have a defence if they comply with the Small Business Fair Dismissal Code. In addition, employees must be covered by an award or enterprise agreement, and have an income below $167,500 in July 2023 (the "high income threshold"). Another exception is that "casual" employees have no rights unless they have a "reasonable expectation of continuing employment by the employer on a regular and systematic basis". In Ponce v DJT Staff Management Services a traffic controller employed through a labour hire firm, and classed as "casual", had unpredictable work shifts and some breaks in work, but was still held to have had work on a regular and systematic basis. Unlike in most high income countries, the Fair Work Act 2009 fails to treat expiry of fixed-term contracts as a dismissal that must be fair. The meaning of dismissal includes termination, or being forced to resign by the employer's conduct, or demotion with a significant reduction of pay or duties.
Sources: en.wikipedia.org
=== Guidelines === American Association of Blood Banks Clinical Practice Guidelines Australian National Blood Authority Patient Blood Management Guidelines British Committee for Standards in Haematology National Institute for Health and Care Excellence Blood Transfusion Guidance UK Guidance for transfusion. Canadian Blood Transfusion Guidelines German Medical Association Guidelines (English) Archived 2022-04-01 at the Wayback Machine, published 2014.
chemotaxis A directed, non-random change in the movement of a molecule, cell, or organism in response to a chemical stimulus, e.g. towards or away from an area with a high concentration of a particular chemical compound.
While there have historically been other notable socialist members of Congress and other public offices in the United States, such as former House whip David Bonior, former New York City mayor David Dinkins, and the initial sponsor of the Medicare for All Act, John Conyers, it is widely held that Bernie Sanders was the first to bring democratic socialism into widespread popularity in the United States. Sanders, who was the 37th Mayor of Burlington and later a member of the United States House of Representatives, became the first self-described democratic socialist to be elected to the Senate from Vermont in 2006. In 2016, Sanders made a bid for the Democratic Party presidential candidate, thereby gathering considerable popular support and interest in his campaign and democratic socialism, particularly among the younger generation and the working class. Although the nomination ultimately went to centrist Hillary Clinton, Sanders ran again in the 2020 Democratic Party presidential primaries, briefly becoming the front-runner. Since his praise of the Nordic model indicated focus on welfare programs as opposed to views involving social ownership, it has been argued that the term democratic socialism has become a misnomer for social democracy in American politics. Nonetheless, Sanders has explicitly advocated for some form of public ownership as well as workplace democracy, an expansion of worker cooperatives and the democratisation of the economy.
== Macrophage activated phenotypes == Macrophages inherently display tissue and environment-dependent plasticity. In addition, the phenotypes of the macrophages in a certain environment play a fundamental role in determining the immune activity and response within the tissue. Depending on the combination of MAFs signaling to the macrophage, the macrophage’s activated phenotype becomes one of three major categories: classically activated, wound healing, or regulatory. Regulatory-phenotype macrophages have only recently been recognized as an important contributor to tissue microenvironments. Tumor-associated macrophages may be any of these types, and they have been found to be important players in the tumor microenvironment. Analysis of the macrophage population and signaling in a tumor may provide useful clinical data.
Sources: en.wikipedia.org
Somalia's foreign relations are handled by the President as the head of state, the Prime Minister as the head of government, and the federal Ministry of Foreign Affairs. According to Article 54 of the national constitution, the allocation of powers and resources between the Federal Government and the Federal Republic of Somalia's constituent Federal Member States shall be negotiated and agreed upon by the Federal Government and the Federal Member States, except in matters pertaining to foreign affairs, national defence, citizenship and immigration, and monetary policy. Article 53 also stipulates that the Federal Government shall consult the Federal Member States on major issues related to international agreements, including negotiations vis-a-vis foreign trade, finance and treaties. The Federal Government maintains bilateral relations with a number of other central governments in the international community. Among these are Djibouti, Ethiopia, Egypt, the United Arab Emirates, Yemen, Turkey, Italy, the United Kingdom, Denmark, France, the United States, the People's Republic of China, Japan, Russian Federation and South Korea. Additionally, Somalia has several diplomatic missions abroad. There are likewise various foreign embassies and consulates based in the capital Mogadishu and elsewhere in the country. Somalia is also a member of many international organisations, such as the United Nations, African Union and Arab League. It was a founding member of the Organisation of Islamic Cooperation in 1969.
Epimedium, also known as barrenwort, bishop's hat, fairy wings, horny goat weed, or yin yang huo (Chinese: 淫羊藿; pinyin: Yínyánghùo; Wade–Giles: Yin²-yang²-huo⁴), is a genus of flowering plants in the family Berberidaceae. The majority of the species are endemic to China, with smaller numbers elsewhere in Asia and a few in the Mediterranean region. Epimedium species are deciduous or evergreen hardy perennials. The majority have four-parted "spider-like" flowers in spring. The species used as a dietary supplement is Epimedium grandiflorum. It contains icariin, which is a weak PDE5 inhibitor, in vitro. Its clinical effects are unknown. While there is little clinical evidence to date, as sildenafil, vardenafil, and tadalafil–sold under the brand names Viagra, Levitra and Cialis–are all based on (stronger) PDE5 inhibitory action, it is thought to have erectogenic properties and is found in some men's sexual health supplements.
==== High levels in saliva and capillary blood ==== On the basis of the very low levels of progesterone observed in venous blood with transdermal progesterone, some researchers have concluded that transdermal progesterone is not well-absorbed and will not allow for adequate endometrial protection. However, in spite of very low levels of progesterone in circulation, studies that have measured levels of progesterone in saliva and/or capillary blood with transdermal progesterone have found that they are dramatically elevated and in fact greatly supraphysiological. In one study that used an oil-based cream or water-based gel, salivary and fingertip capillary blood levels of progesterone were found to be approximately 10-fold and 100-fold greater than venous blood levels, respectively. The exact levels of progesterone were 4 to 12 ng/mL in saliva and 62 to 96 ng/mL in capillary blood; the reference ranges of progesterone in saliva and capillary blood from a cited laboratory were 0.75 to 2.5 ng/mL and 3.3 to 22.5 ng/mL for premenopausal women in the luteal phase and 0.12 to 1.0 ng/mL and 0.1 to 0.8 ng/mL in postmenopausal women, respectively. As such, these data confirm distribution of progesterone to at least certain tissues with transdermal progesterone in spite of very low levels of progesterone in circulation and indicate that progesterone levels in venous blood cannot necessarily be used as an index of tissue exposure to progesterone with this route of administration.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.